Idera Pharmaceuticals Announces Appointment of Howard Pien to its Board of Directors
September 18 2018 - 4:01PM
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical
company focused on the development and commercialization of its
proprietary immune modulator, tilsotolimod, for the treatment of
cancer, today announced that Howard Pien joined its Board of
Directors, effective September 18, 2018.
Mr. Pien has worked in the pharmaceutical and biotechnology
industries for more than three decades. In addition to Idera,
Mr. Pien serves as the Non-executive Chairman of Indivior PLC.
Previously Mr. Pien was the Lead Independent Director of ViroPharma
Incorporated, Chairman of the Board of Vanda Pharmaceuticals and
Chairman of the Board of Directors of Juno Therapeutics. Mr.
Pien’s additional prior Board service includes Ikaria Inc.,
Immunogen, Inc. and Sage Therapeutics.
Mr. Pien was the Chairman of the Board and Chief Executive
Officer of Medarex, Inc, until it was acquired by Bristol-Myers
Squibb and Chairman of the Board and Chief Executive Officer of
Chiron Corporation, until it was acquired by Novartis. Mr.
Pien was the President of Pharmaceuticals at SmithKline Beecham and
the President of International of GlaxoSmithKline. Early in
his career, Mr. Pien served in roles at Abbott Laboratories and
Merck & Co. Mr. Pien received a B.S. from MIT and an
M.B.A. from Carnegie Mellon University.
“I am pleased to welcome Howard to the Idera Board,”
stated Jim Geraghty, Chairman of Idera’s Board of
Directors. “Howard’s exceptional experience in building
industry-leading companies will be a tremendously valuable
addition as Idera continues its growth toward becoming a
patient-focused commercial biotechnology company.”“I am thrilled to
in a position of working together with Howard again,” stated
Vincent Milano, Idera’s Chief Executive Officer. “My
experience of Howard’s presence in a board setting through my time
when we were together at ViroPharma was incredibly appreciated and
rewarding and I am looking forward to continuing that collaborative
effort here at Idera.”
The company today is also announcing that Mr. Julian Baker of
Baker Brothers Investments, is stepping down from the Board of
Directors effective September 18, 2018. Mr. Baker has served
on the Idera Board of Directors since 2014. During his time
on the Board, Mr. Baker played an integral role in providing
strategic guidance and also was instrumental in shaping the
company’s current leadership team ultimately bringing a new level
of strategic focus to Idera.
“I have appreciated the opportunity to serve on the Board of
Idera for the past four years,” stated Julian C. Baker. “I have the
utmost confidence in Vin and his leadership team. I fully
support the direction that they are leading Idera to enhance
shareholder value over the long term.”
About Idera PharmaceuticalsHarnessing the
approach of the earliest researchers in immunotherapy and Idera’s
experience in developing proprietary immunology technologies,
Idera’s lead development program is focused on priming the immune
system to play a more powerful role in fighting cancer, ultimately
increasing the number of people who can benefit from immunotherapy.
Idera is committed to working with investigators and partners who
share the common goal of addressing the unmet needs of patients
suffering from difficult to treat, unmet cancers. To learn more
about Idera, visit www.iderapharma.com.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements, other than statements of historical fact, included
or incorporated in this press release, including statements
regarding the Company’s strategy, future operations,
collaborations, cash resources, financial position, future
revenues, projected costs, prospects, clinical trials, plans and
objectives of management, are forward-looking statements. The words
“believes,” “anticipates,” “estimates,” “plans,” “expects,”
“intends,” “may,” “could,” “should,” “potential,” “likely,”
“projects,” “continue,” “will,” and “would” and similar expressions
are intended to identify forward-looking statements, although not
all forward-looking statements contain these identifying words.
Idera cannot guarantee that it will actually achieve the plans,
intentions or expectations disclosed in its forward-looking
statements and you should not place undue reliance on the Company’s
forward-looking statements. There are a number of important factors
that could cause Idera’s actual results to differ materially from
those indicated or implied by its forward-looking statements,
including whether the Company’s cash resources will be sufficient
to fund the Company’s continuing operations and the further
development of the Company’s programs for the period anticipated;
whether interim results from a clinical trial will be predictive of
the final results of the trial; whether results obtained in
preclinical studies and clinical trials will be indicative of the
results that will be generated in future clinical trials; whether
products based on the Company’s technology will advance into or
through the clinical trial process when anticipated or at all or
warrant submission for regulatory approval; whether such products
will receive approval from the U.S. Food and Drug Administration or
equivalent foreign regulatory agencies; whether, if the Company's
products receive approval, they will be successfully distributed
and marketed; whether the Company's collaborations will be
successful; and such other important factors set forth under the
caption “Risk Factors” in the Company’s Annual Report on Form 10-K
for the period ended December 31, 2017 and in the Company’s
Quarterly Report on Form 10-Q for the period ended June 30, 2018.
Although Idera may elect to do so at some point in the future, the
Company does not assume any obligation to update any
forward-looking statements and it disclaims any intention or
obligation to update or revise any forward-looking statement,
whether as a result of new information, future events or
otherwise.
Investor and Media ContactRobert DoodyVice
President, Investor Relations and Corporate CommunicationsOffice:
484-348-1677rdoody@iderapharma.com
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Jul 2023 to Jul 2024